Umbilical Cord Blood as an Alternative Source of Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Epstein-Barr Virus–Associated T or Natural Killer Cell Lymphoproliferative Diseases  by Sawada, Akihisa et al.
Biol Blood Marrow Transplant 20 (2014) 214e221American Society for Blood
ASBMT
and Marrow TransplantationUmbilical Cord Blood as an Alternative Source of
Reduced-Intensity Hematopoietic Stem Cell Transplantation
for Chronic Epstein-Barr ViruseAssociated T or Natural
Killer Cell Lymphoproliferative Diseases
Akihisa Sawada*, Masami Inoue, Maho Koyama-Sato, Osamu Kondo,
Kayo Yamada, Mariko Shimizu, Kanako Isaka, Tomiko Kimoto,
Hiroaki Kikuchi, Sadao Tokimasa, Masahiro Yasui, Keisei Kawa
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, JapanArticle history:
Received 15 August 2013
Accepted 30 October 2013
Key Words:
Chronic active EBV infection
Hypersensitivity to mosquito
bites
Severe-type hydroa
vacciniforme
Reduced-intensity conditioning
Cord blood transplantationFinancial disclosure: See Acknowl
* Correspondence and reprint
Associate Director, Department o
Center and Research Institute for M
Izumi City, Osaka 594-1101, Japan.
E-mail address: asawada@mch.
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Chronic Epstein-Barr viruseassociated T/natural killer cell lymphoproliferative diseases represented by
chronic active Epstein-Barr virus infection are lethal but are curable with several courses of chemotherapy
and allogeneic hematopoietic stem cell transplantation (HSCT). Recently, we reported that reduced-intensity
conditioning (RIC) provided better outcomes than myeloablative conditioning because RIC was less toxic.
However, it was unclear whether cord blood transplantation (CBT) works in the context of RIC. We retro-
spectively analyzed 17 patients who underwent RIC followed by bone marrow transplantation (RIC-BMT) and
15 patients who underwent RIC followed by CBT (RIC-CBT). The representative regimen was ﬂudarabine and
melphalan based. The overall survival rates with RIC-BMT and RIC-CBT were 92.9%  6.9% and 93.3%  6.4%,
respectively (P ¼ .87). One patient died of lung graft-versus-host disease after RIC-BMT, and 1 patient died of
multiple viral infections after RIC-CBT. Although cytotoxic chemotherapy was also immunosuppressive and
might contribute to better donor cell engraftment after RIC-HSCT, the rate of engraftment failure after RIC-
CBT was still higher than that after RIC-BMT (not signiﬁcant); however, patients who had experienced
graft failure were successfully rescued with a second HSCT. Unrelated cord blood can be an alternative source
for RIC-HSCT if a patient has no family donor.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Epstein-Barr virus (EBV), also known as human herpes-
virus 4, is a B cell lymphotropic and oncogenic virus and
occasionally causes a variety of B cell lymphoproliferative
diseases (LPDs) [1]. However, latent EBV infection can occur
in T cells and/or natural killer cells (T/NK cells), resulting in T/
NK cell LPDs [2,3]. Chronic EBV-associated T/NK cell LPDs
(EBVþ T/NK cell LPDs) are 1 of 3 distinct types of EBVþ T/NK
cell LPDs (acute type, chronic type, and malignant type) [1,4].
Chronic EBVþ T/NK cell LPDs are represented by chronic
active EBV infection (CAEBV) that is sometimes accompanied
by hypersensitivity to mosquito bites or severe-type hydroa
vacciniforme, but hypersensitivity to mosquito bites and
severe-type hydroa vacciniforme also occur independently of
CAEBV [5].
Chronic EBVþ T/NK cell LPD is not a simple chronic dis-
ease, but its ﬂare could result in a rapid, irreversible, and fatal
clinical course. A study found that more than 60% of patients
died over several years, mainly due to organ failure (such as
liver and heart), hemophagocytic syndrome (HPS), and
lymphoma [6]. Allogeneic hematopoietic stem cell trans-
plantation (HSCT) is the only cure for the patients with
chronic EBVþ T/NK cell LPD [7], although rare exceptionsedgments on page 221.
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13.10.026were reported in which complete molecular remission was
achieved with multidrug chemotherapy [8].
Reduced-intensity conditioning (RIC) and umbilical cord
blood transplantation (CBT) were developed in the 2000s.
RIC is less toxic than myeloablative conditioning in regard to
reducing transplant-related mortality, allowing growth and
development in children, and to retaining fertility in young
adults [9]. In our previous report on chronic EBVþ T/NK cell
LPD, RIC followed by HSCT (RIC-HSCT) brought about better
outcomes (survival rate > 90%) than myeloablative
conditioning-HSCT, and we found that CBT, as well as bone
marrow transplantation (BMT), might lead to a cure in these
patients [10]. However, the number of cases of RIC-CBT was
too small to discuss its efﬁcacy in that report. Unrelated CBT
is potentially promising because, as opposed to unrelated
bone marrow, unrelated cord blood (CB) is immediately
available. However, CB lymphocytes are naive and do not
have speciﬁc immune memories to EBV, whereas most adult
lymphocytes have been exposed to and are immune to EBV;
it is possible that this difference can inﬂuence the post-
transplant clinical courses and immune reconstruction to
EBV. In addition, donor lymphocyte infusion is not available
after CBT.
The aim of this retrospective analysis using our latest
institutional registration and follow-up data was to clarify
whether RIC-CBT could be an alternative treatment for the
patients with chronic EBVþ T/NK cell LPD if there is no family
donor. This study was approved by the Research Ethics
Committee of Osaka Medical Center and Research Institute
for Maternal and Child Health.Transplantation.
Figure 1. Patient selection. Fifty-six patients with EBVþ T/NK cell LPD were
treated with allogeneic HSCT at our institute. Selection criteria for the current
study were chronic EBVþ T/NK cell LPD, RIC, and BMT or CBT. Two patients who
underwent RIC-BMT were also excluded because of individualized less-intensity
conditioning for kidney dysfunction (n ¼ 1) and compassionate transplantation
for uncontrollable fulminant hemophagocytic lymphohistiocytosis (n ¼ 1). EBV-
AHS indicates EBV-associated hemophagocytic syndrome; MAC, myaloablative
conditioning; PBSCT, peripheral blood stem cell transplantation.
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Patients
Patients with CAEBV met the criteria proposed in 2005 [11]. Fifty-six
patients with EBVþ T/NK cell LPD were treated with allogeneic HSCT be-
tween March 1997 and December 2011 at our institute (Figure 1). WeFigure 2. Conditioning regimen. Closed circles indicate ﬁxed administration, and ope
which tended to be used for BMT. The problems were a high rate of EBVþ post-transp
variable diseases other than EBVþ T/NK cell LPD and then no availability of antilymp
which tended to be used for CBT. The problem was a usage of irradiation, which mig
istration. (C) Current regimen universally administered for BMT and CBT since January
d and CA 20 mg/m2/d were administered for 24 hours continuously for a median of 9 da
irradiation; mPSL, methylprednisolone; CY, cyclophosphamide.excluded 5 patients from the analysis because their diagnoses were hemo-
phagocytic lymphohistiocytosis as acute EBV infection (n ¼ 3) or malignant
lymphoma (n ¼ 2). Of the 51 patients with chronic EBVþ T/NK cell LPD, 44
had a diagnosis of CAEBV, 5 had a diagnosis of hypersensitivity to mosquito
bites, and 2 had a diagnosis of severe-type hydroa vacciniforme without
clinical manifestation of CAEBV.
Because all CBTs were performed after RIC and because the overall sur-
vival (OS) rate after myeloablative conditioning (median  standard error,
54.5%  15.0%) was signiﬁcantly inferior to that after RIC in regard to toxicity
[10], patients who underwent myeloablative conditioning-HSCT (n ¼ 11)
were excluded from further analysis. There were 40 cases of RIC-HSCT. Six
patients who underwent peripheral blood stem cell transplantation were
excluded because peripheral blood stem cell transplantation tended to be
used in patients with severe complications or other high-risk conditions:
poorly controlled pneumonia with Pseudomonas aeruginosa (n ¼ 1), severe
heart dysfunction (n ¼ 2), persistent HPS with febrile neutropenia (n ¼ 1),
and HLA 3/6 allele-mismatched HSCT (n ¼ 2). The hematopoietic cell
transplantation-speciﬁc comorbidity index (HCT-CI) of these 6 patientswas a
median of 1 (range, 0 to 4) [12].
Two additional patients were excluded: 1 was treated with individual-
ized less-intensity conditioning for kidney dysfunction (including ﬂudar-
abine [Flu] 100 mg/m2 and melphalan [LPAM] 50 mg/m2) and experienced
donor-cell rejection after BMT (HCT-CI ¼ 0), and 1 had uncontrolled
fulminant CAEBV-associated HPS with adenovirus hemorrhagic cystitis at
the initiation of RIC and died of progressive primary disease at 4 days after
compassionate BMT (HCT-CI ¼ 6). As a result, the analysis includes 17 pa-
tients who underwent RIC-BMT (related, n ¼ 11; unrelated n ¼ 6) and 15
patients who underwent unrelated RIC-CBT. The HCT-CI of these 17 and 15
patients were all 0.Detection of EBV
Identiﬁcation of EBV-infected cells and measurement of EBV load have
been described elsewhere [10]. Brieﬂy, for identiﬁcation, the EBV genome
was ampliﬁed by PCR in DNA extracted from each lymphocyte subset in
peripheral blood, or EBV-encoded small ribonucleic acid (EBER) and surfacen circles indicate optional administration. (A) Standard conditioning regimen,
lant LPD at a total antilymphocyte globulin dose of 40 mg/kg in patients with
hocyte globulin afterward. (B) Conditioning regimen for high risk of rejection,
ht induce a higher rate of subsequent neoplasms compared with drug admin-
2010. ALG indicates anti-lymphocyte globulin LDEC, low-dose Etp 30 mg/m2/
ys (range, 4 to 14 days) just before RIC with Flu þ LPAM; TAI, thoracoabdominal
Table 1
Patient Characteristics
Graft Source
A. Sawada et al. / Biol Blood Marrow Transplant 20 (2014) 214e221216markers were stained on thin-sliced tissue from involved organs such as
liver and skin. EBV load was measured using real-time quantitative PCR in a
commercial laboratory (BML Inc., Tokyo, Japan), and the lower limit of
detection was 200 copies/mL in whole blood [13].BMT (n ¼ 17) CBT (n ¼ 15)
Age at onset
0-9 yr 6 (35%) 13 (87%)
10-19 yr 4 (24%) 0
20-29 yr 2 (12%) 1 (7%)
30 yr 5 (29%) 1 (7%)
Sex
Male 7 (41%) 5 (33%)
Female 10 (59%) 10 (67%)
Diagnosis
CAEBV 13 (76%) 6 (40%)
CAEBVþHMB 1 (6%) 5 (33%)
HMB 3 (18%) 2 (13%)
SHV 0 2 (13%)
EBV-infected subset
T 6 (35%) 7 (47%)
NK 9 (53%) 8 (53%)
TþNK 2 (12%) 0
Donor relation
Related MS 7 (41%) 0
Non-MS 4 (24%) 0
Unrelated 6 (35%) 15 (100%)
HMB indicates hypersensitivity to mosquito bite; SHV, severe-type hydroa
vacciniforme; MS, HLA-matched sibling donor.Treatment before HSCT
Patients with active disease such as fever and hepatitis were initially
treated with immunochemotherapy including prednisolone (PSL) 1 to
2 mg/kg/d, cyclosporine A 3 mg/kg/d, and etoposide (Etp) 150 mg/m2/wk
from 1 to several weeks until symptoms were controlled. Patients were then
treated with at least 2 courses of combination chemotherapy such as a
modiﬁed CHOP regimen, high-dose cytosine arabinoside (CA), L-asparaginase,
or their reduced doses in combination [10]. Modiﬁed CHOP consisted of
cyclophosphamide 750 mg/m2/d (day 1), pirarubicin 25 mg/m2/d (days 1 and
2), vincristine 2 mg/m2/d (maximum dose, 2 mg) (day 1), and PSL 50 mg/m2
(day 1). High-dose CA consisted of CA 1.5 g/m2 twice a day (days 1 to 6) and
PSL 30 mg/m2/d (days 1 to 6). VPL consisted of Etp (VP-16) 150 mg/m2/d (day
1), PSL 30 mg/m2/d (days 1 to 7), and L-asparaginase 6000 U/m2/d (days 1 to
7). Capizzi consisted of CA 3 g/m2 4 times (every 12 hours) and L-asparaginase
10,000 U/m2 once (4 hours post-CA) and PSL 30 mg/m2/d (days 1 and 2).
ESCAP consisted of Etp 150 mg/m2/d (day 1), CA 1.5 g/m2 8 times (every
12 hours), L-asparaginase 6000 U/m2/d for 5 days (4 hours post-CA and
following days), methylprednisolone 125 mg/m2/d (days 1 to 4), and PSL
30 mg/m2/d (days 5 to 8).
As the initial combination chemotherapy, CHOP therapy was adminis-
tered to 82.4% of patients in the RIC-BMT group and 93.3% of patients in the
RIC-CBT group. As the second chemotherapy, ESCAP, Capizzi, and VPL were
administered to 47.1%, 29.4%, and 11.8% of patients in the RIC-BMT group,
respectively, and ESCAP, Capizzi, and VPL were administered to 40.0%, 26.7%,
and 13.3% of patients in the RIC-CBT group, respectively. Patients in the RIC-
BMTgroup underwent amedian of 3 courses of pretransplant chemotherapy
(range, 2 to 6), and patients in the RIC-CBT group underwent a median of 3
courses as well (range, 2 to 5).HSCT Procedure
The conditioning regimen for patients treated with extensive courses of
chemotherapy was Flu 120 to 180 mg/m2 and LPAM 140 mg/m2 with or
without antilymphocyte globulin 20 to 40 mg/kg (Figure 2). The condi-
tioning regimen for other patients was Flu 180 mg/m2, LPAM 70 mg/m2,
cyclophosphamide 50 mg/kg, and thoracoabdominal irradiation 4 to 6 Gy
with or without antilymphocyte globulin 20 to 40 mg/kg. Since January
2010, a revised universal conditioning regimen of Flu 180 mg/m2, LPAM
140 mg/m2, and antithymocyte globulin 2.5 mg/kg was administered for
both BMT and CBT.
Since 2009, most patients were treated before conditioning with intra-
venous low-dose Etp 30 mg/m2/d and CA 20 mg/m2/d for 24 hours contin-
uously for a median of 9 days (range, 4 to 14 days) as a pre-RIC treatment to
reduce the burden of EBVþ T/NK cells and the risk of rejection. Most patients
received Etp 100 mg/m2/d for 2 to 3 days to delete activated histiocytes
(HPS induced by conditioning-related tumor lysis) and to reduce the inci-
dence of graft-versus-host disease (GVHD). GVHD prophylaxis included
cyclosporine A for HLA-matched related BMT; tacrolimus and a short course
of methotrexate for HLA-mismatched CBT; HLA-mismatched related BMTFigure 3. Survival rates after HSCT. (A) EFS and (B) OS after HSCTand HLA-matched unrelated BMT; and tacrolimus, short course of metho-
trexate, and methylprednisolone for HLA-mismatched unrelated BMT.
Patients were prophylactically treated with ganciclovir at 5 mg/kg
intravenously every 12 hours before HSCT (from days e8 to e1) when they
were serologically positive for cytomegalovirus (CMV), and all patients
received acyclovir at 600 mg/m2/d orally after HSCT [13]. CMV antigenemia
was monitored with antibodies C10/C11 against CMV pp65 every week
(high-risk patients) or every other week after engraftment. Patients were
preemptively treated with ganciclovir when the pp65-positive cell number
was 10/150,000 WBCs. Patients with CMV or human herpesvirus 6 disease
were immediately treated with ganciclovir or foscarnet.Endpoints and Deﬁnition
The primary endpoint was OS, deﬁned as the duration from HSCT to any
death. Second HSCT was not censored in OS. Patients remaining alive at the
last follow-up were censored. Event-free survival (EFS) was deﬁned as the
duration from HSCT to any event: recurrence of disease, transplant-related
mortality, and second HSCT (due to engraftment failure or loss of donor
chimerism). EBV-associated LPD of donor-cell origin was regarded as in-
fectious disease but not as recurrence of disease or subsequent primary
malignancy.
The date of neutrophil recoverywas considered the ﬁrst of 3 consecutive
days the absolute neutrophil count exceeded 500/mL. Engraftment failure. Solid lines represent CBT, and dotted lines represent BMT.
Table 2
Events and Causes of Death
BMT CBT (n ¼ 15) BMT
vs. CBT
P
MS or R (6/6)
(n ¼ 10)
U or R (5/6)
(n ¼ 7)
Regimen
FluþLPAMALG
based
5 2 3
LAPMþFluþCYþTAI
based
3 1 6 d
ATGþFluþLPAM
based
2 4 6
Engraftment failure
Autorecovery/
persistent
neutropenia
0/1 0 1*/2 .23
/Second HSCT /1 d /3
/Complete donor
chimerism
/1 d /3
Acute GVHD
Grades II-IV/
assessable
number
6/9 (67%) 3/7 (43%) 6/12 (50%) .74
Grades III-IV/
assessable
number
2/9 (22%) 2/7 (29%) 1/12 (8%) .25
Chronic GVHD
LimþExt/assessable
number
6/9 (67%) 3/7 (43%) 5/12 (42%) .74
Ext/assessable
number
6/9 (67%) 2/7 (29%) 1/12 (8%) .02
Viral reactivation/
infection
CMV antigenemia 2 5 10y .17
CMV disease 1 0 2y .47
EBVþPTLD 1 1 1 .62
HHV6 diseases 1 0 2 .47
BKV hemorrhagic
cystitis
1 0 5y,z .05
Death
GVHD 1 (BO) 0 0 d
Viral disease 0 0 1
(CMVþBKV)y
d
R(6/6) indicates a related donorwhowas not an HLA-matched sibling but had
serologically matched HLA-A, -B, and -DR for graft-versus-host (GVH) direc-
tion; R(5/6), related donor who had serologically one-mismatched HLA for
GVH direction; assessable patient number in acute and chronic GVHD, pa-
tientswho achieved complete donor chimerism after ﬁrst HSCT;MS,matched
sibling; ALG, antilymphocyte globulin; ATG, antithymocyte globulin; TAI,
thoracoabdominal irradiation; PTLD, post-transplant lymphoproliferative
disease; BO, bronchiolitis obliterans as a lung GVHD.
HHV6 diseases were encephalitis (after BMT), skin rash (CBT) and pneumo-
nitis (CBT).
* One patient showed recipient chimerism 100% but had incomplete
hematopoiesis.
y One patient with BKV cystitis developed lethal systemic BKV infection
and CMV pneumonitis.
z PCR for BKV detection was not performed in 1 of 5 patients with
hemorrhagic cystitis.
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5% in WBCs from peripheral blood at day 28 after HSCT. Continuous com-
plete donor chimerism was deﬁned as a neutrophil count > 500/mL and
donor-type WBCs > 95% in peripheral blood at day 28 and later, and mixed
chimerism was deﬁned as a neutrophil count > 500/mL and donor-type
WBCs 5% to 95% in peripheral blood at day 28 or later.
Statistics
Statistical analyses were performed using the SPSS version 14 (SPSS Inc.,
Chicago, IL). Survival rate was estimated with the Kaplan-Meier method and
assessed with the log-rank test. Chi-square test was used for univariate
analysis.
RESULTS
The characteristics of the 32 patients included in the study
are shown in Table 1. Fifteen of 32 patients were included in
our previous report [10]. There was a signiﬁcant difference in
age between patients in the RIC-BMT and RIC-CBT groups. In
these 32 patients, the EFS rate was 83.4%  6.8% and the OS
rate was 92.8%  4.9%.
The EFS rate of patients treated with RIC-BMT and RIC-
CBT was 86.9%  8.7% and 80.0%  10.3%, respectively,
whichwas not statistically signiﬁcant (P¼ .51, Figure 3A). The
OS rate of patients treated with RIC-BMT and RIC-CBT was
92.9%  6.9% and 93.3%  6.4%, respectively, again not sta-
tistically signiﬁcant (P ¼ .87, Figure 3B). However, interest-
ingly, there were some differences in the clinical courses
after HSCT between patients treated with RIC-BMT and pa-
tients treated with RIC-CBT, as shown in the following text.
Engraft Failure
The HSCT procedure and results are shown in Table 2. Four
patients experienced rejection, mixed chimerism, or autolo-
gous hematological recovery: 1 in the RIC-BMTgroup and 3 in
the RIC-CBT group. Of these 4 patients, elevation of EBV load
was documented in 2 (unique patient number [UPN] 463 and
605). A girl (UPN 463) experienced neutrophil recovery of
complete autologous cells (donor 0%) day 35 after RIC-CBT
using regimen B shown in Figure 2. However, she was
continuously dependent on red blood cell and platelet infu-
sion and granulocyte colony-stimulating factor afterward,
and EBV load was elevated 2  104 copies/mL (whole blood)
without symptoms. She successfully underwent a second
RIC-CBT [10]. Three other patients (1 treated with RIC-BMT
and 2 treated with RIC-CBT) experienced rejection without
neutrophil recovery after the current regimen C for condi-
tioning (Table 3). A girl (UPN 573) had a homozygote of HLA
allelotype that resulted in no HLA mismatched to graft-
versus-host direction and 2 alleles mismatched only to
rejective direction. She successfully underwent RIC-
peripheral blood stem cell transplantation from the same
donor (her father) of the ﬁrst RIC-BMT. A girl (UPN 569) had
bidirectional 2 allele mismatches, and a boy (UPN 605) had
bidirectional 3 allele mismatches to the CBT donor; here, no
anti-HLA antibody or antibody against donor cells, which
might be related to lower neutrophil and platelet recovery,
was detected in their plasma [14]. CB contained a sufﬁcient
number of WBCs and hematopoietic stem/progenitor cells.
These patients underwent a second RIC-CBT and had com-
plete donor chimerism.
Graft-versus-Host Disease
No differences were found in the occurrence of acute and
chronic GVHD between patients treated with RIC-BMT and
those treated with RIC-CBT. A high ratio of severe acute and
extensive chronic GVHDwas observed in the RIC-BMTgroup,but the signiﬁcance was statistically demonstrated only with
extensive chronic GVHD (Table 2). No differences were seen
in the occurrence and the severity of acute and chronic GVHD
between HLA-matched related donors and unrelated or
HLA-mismatched related donors; indeed, 1 patient who
underwent matched-sibling BMT died of GVHD (UPN 563,
mentioned later).
Viral Infection and Reactivation
There was no difference in the occurrence of CMV, EBV,
and human herpesvirus-6 diseases between patients treated
with RIC-BMTand those treated with RIC-CBT. A high ratio of
signiﬁcance appeared only with the occurrence of BK virus
Table 3
Current Regimen and Engraftment
UPN Age
(yr)
Sex Body
Weight
(kg)
Source No. Mismatched
HLA
Conditioning No. Courses
Chemotherapy
EBV Load at RIC
(Copies/mL)
Conditioning-
Associated HPS
GVHD
Prophylaxis
Infused Cells Anti-
HLA Ab
Results
Rejection
Direction
GVH
Direction
ABDR Cw ABDR Cw LDEC
(Days)
ATG
(mg/
kg)
FluþLPAM
(mg/m2)
Etp
(mg/
m2)
ANC
(107/
kg)
CD34þ[105/
kg]
Neutrophil
Recovery
Engraftment
(Chimerism)
563 36 F 51 MS-
BM
0 0 0 0 4 2.5 F180þL140 200 2 8  105  CsA 33.9 92.7 ND þ Donor
607 11 M 33 U-BM 0 0 1 0 10 2.5 F180þL140 200 3 2  104  CsA/sMTX/
mP
36.7 33.6 ND þ Donor
588 37 F 47 U-BM 0 0 0 0 7 2.5 F180þL140 200 4 1  104  Tac/sMTX 32.5 39.1 ND þ Donor
556 25 F 54 U-BM 0 1 0 1 9 - F180þL140 300 3 <200  Tac/sMTX 32.3 24.1 ND þ Donor
595 15 M 53 U-BM 1 1 1 0 6 2.5 F180þL210* 200 3 7  104  Tac/sMTX/
mP
27.0 27.6 ND þ Donor
573 11 F 33 R-BM 2 1 0 0 12 - F180þL140 300 2 1  104  Tac/sMTX 50.6 67.3 ND  Failure
584 23 F 46 U-CB 1 1 1 1 11 2.5 F180þL140 300 5 3  104  Tac/sMTX 3.41 0.96 Neg þ Donor
582 11 F 42 U-CB 2 0 2 1 9 2.5 F180þL140 300 4 2  104  Tac/sMTX 4.19 1.63 Neg þ Donor
569 10 F 42 U-CB 2 0 2 0 14 2.5 F180þL140 300 2 2  104 þ Tac/sMTX 3.36 0.84 Neg  Failure
571 9 M 44 U-CB 2 0 2 0 14 2.5 F180þL140 300 2 5  104 þ Tac/sMTX 2.37 0.80 ND þ Donor
605 9 M 28 U-CB 2 1 2 1 7 2.5 F180þL140 200 2 4  104 þ Tac/sMTX 3.93 1.46 Neg  Failure
603 38 M 61 U-CB 2 2 2 1 8 2.5 F180þL140 300 2 3  104 þ Tac/sMTX 1.64 1.23 Neg þ Donor
UPN indicates unique patient number; F, ﬂudarabine; L, LPAM; LDEC, low-dose Etp and cytosine arabinoside as a pre-RIC treatment; ATG, antithymocyte globulin; GVH, graft-versus-host; ANC, all nucleated cells; CD34þ, CD34-
positive cells; Ab, antibody; MS, matched sibling; R, HLA-mismatched related; U, unrelated; BM, bone marrow; CsA, cyclosporine A; sMTX, short course of methotrexate; mP, methylprednisolone; Tac, tacrolimus; neg, negative;
ND, not done.
The numbers of mismatched-HLA alleles (genotype) in HLA-Aþ Bþ DRB1 (ABDR) and in HLA-Cw are separately shown. The order of patients is from low risk to high risk of rejection; that is, ascending in rejection direction, then
descending in GVHD direction. Age and body weight are at the initiation of conditioning.
* One day of additional LPAM (70 mg/m2/d  3 days in total) because more than 1 year had passed since the latest chemotherapy.
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Figure 4. Anti-EBV antibody titers after HSCT. (A-D) The changes in antieEBV-VCA IgG titers, followed for at least 1 year after HSCT, are shown. (A) BMT from a donor
whose EBV-VCA IgG was known (n ¼ 6, all were positive for EBV-VCA IgG). Open triangles represent UPN 563, who had EBVþ B cell post-transplant LPD (PTLD). (B-D)
CBT (n ¼ 9). (B) EBV-VCA IgG titer has never achieved an undetectable level (<1:10) in 4 of 9 recipients after CBT. Engrafted B cells might be infected with recipient-
derived EBV, because CB is regarded as free from EBV. The lowest titers were observed during 6 to 18 months after BMT and CBT (A and B). (C) EBV-VCA IgG titer
remained negative 12 months after CBT in 3 recipients. Recipient EBV might be eradicated by CBT. (D) UPN 432 had severe PTLD after secondary primary EBV
infection: EBVþ B cell PTLD followed by EBVþ NK cell PTLD. Those lymphocytes arise from engrafted donor cells. UPN 494 showed no symptoms. (E-H) Changes in EBV
load are shown. (E) Changes in EBV load of patients in A, (F) those of patients in B, (G) those of patients in C, and (H) those of patients in D. PTLD indicates post-
transplant LPD.
A. Sawada et al. / Biol Blood Marrow Transplant 20 (2014) 214e221 219(BKV) hemorrhagic cystitis, which was statistically higher
after RIC-CBT. One patient experienced lethal viral disease
after RIC-CBT (UPN 569, mentioned later).
AntieEBV virus capsid antigen (VCA) immunoglobulin G
(IgG) titer was followed and measured with a ﬂuorescent
antibody test in a commercial laboratory. The changes in the
titer followed for at least 1 year after HSCT are shown in
Figure 4A-D, and the changes in EBV load are shown in
Figure 4E-H. Three patients experienced EBV-associated
post-transplant LPD (UPN 563 and 607 after BMT and UPN
432 after CBT). UPN 563 (Figure 4A,E) and UPN 607 (not
shown) experienced simple EBVþ B-cell LPD that was suc-
cessfully treated with rituximab 7 and 4 months after BMT,
respectively. However, UPN 432 had severe post-transplantLPD (Figure 4D,H); she experienced symptoms of primary
EBV infection such as sore throat, jaundice, fever, and
lymphadenopathy with EBVþ B-cell LPD in the central ner-
vous system and left eyeground 10months after CBT [15] and
EBVþ NK cell LPD an additional 16 months later. Those cells
were derived from donor-originated lymphocytes and were
fortunately susceptible to R-CHOP and high-dose CA with or
without L-asparaginase, respectively. However, we failed to
prove the EBV was derived from a third party other than the
recipient or the donor [16].
Relapse and Causes of Death
No patient who achieved complete donor chimerism after
the ﬁrst or second HSCT experienced a relapse of primary
Figure 5. Conditioning-associated HPS. Typical conditioning-associated HPS in UPN 603 is shown. HPS (closed star) was controlled by Etp. WBC indicates white blood
cell (/mL); Lym, lymphocyte (/mL); Ferritin, serum ferritin level (ng/mL); sIL2R; soluble interleukin-2 receptor (U/mL); mPSL, methylprednisolone; ATG, antithymocyte
globulin; MTX, methotrexate.
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1 patient (UPN 569) died of multiple viral diseases (hemor-
rhagic BKV cystitis, CMV pneumonitis, and BKV pneumo-
nitis) 61 days after the second RIC-CBT. One woman (UPN
563) died of bronchiolitis obliterans as lung GVHD 541 days
after RIC-BMT.
DISCUSSION
As a source of HSCT that follows the RIC regimen, there
was no inferiority with use of CB in the present analysis. At
the time of HSCT, the median age of patients in the RIC-BMT
group (15 years; range, 5 to 38 years) was older than that of
patients in the RIC-CBT group (9 years; range, 3 to 38 years).
This was simply attributed to the availability of CB (smaller
body weight in younger patients); however, this might
potentially confer a survival advantage to the CBT group,
because adult patients tend to have more complications and
organ dysfunctions than children.
CB may be a favorable source in allogeneic HSCT because
of its easy and immediate accessibility. CBT might also have
superiority because of a lower occurrence rate and lower
severity of GVHD. The adverse results might be mainly
attributed to engraftment failure and disease relapse after
CBT. CB lymphocytes are naive and do not have speciﬁc im-
mune memories to EBV, whereas most adult lymphocytes
have been exposed to and are therefore immune to EBV.
However, no relapse was observed in the patients so far who
achieved complete donor chimerism. The occurrence of
engraftment failure was slightly higher in the RIC-CBT group
than in the RIC-BMT group, but this was not signiﬁcant.
Given that the EBV load was regarded as a minimal residual
disease marker for the efﬁcacy of chemotherapy, most pa-
tients failed to achieve complete molecular remission after
chemotherapy (data not shown); however, chemotherapy
might have more inﬂuence on reducing the engraftment
failure after RIC-CBT. For better engraftment, 3 or more
courses of chemotherapy may be needed (see Table 3);
otherwise, 1 day of additional treatment with LPAM may be
required (LPAM 210 mg/m2 in total, as in UPN 595).
The donors for BMT were all serologically positive for
EBV-VCA IgG and regarded as having EBV latent infection.
The EBV-VCA IgG titer in serum from recipients (n ¼ 6) was
reduced in the ﬁrst 6 months and was maintained to be
positive with a slight increase thereafter (Figure 4A). Therecipients were regarded as harboring persistent (and per-
manent) EBV latent infection, but we could not determine
the present EBV as of recipient origin or donor origin. Four
of 9 patients treated with CBT had a similar pattern of EBV-
VCA IgG (Figure 4B); however, because donor CB is regarded
as free from EBV, engrafted B cells might be infected with
endogenous EBV derived from recipient cells (or reinfected
with a third-party EBV from blood transfusion). On the
other hand, the EBV-VCA IgG level decreased and remains
negative (<1:10) in 3 of 9 recipients after CBT (Figure 4C).
Because the EBV load in blood from the 3 recipients also
remains negative (Figure 4G), it is possible that the
endogenous EBV in these patients was eradicated at the
time of RIC-CBT. However, these patients might be infected
with third-partyederived EBV (secondary primary infec-
tion) by chance; if such an infection occurred before the
patient’s immunity was fully reconstructed (early after
CBT), EBVþ post-transplant LPD would be life threatening,
as seen in UPN 432 (Figure 4D,H). This phenomenon
(eradication of endogenous EBV and reinfection with
exogenous EBV later) was also observed in 2 patients after
BMT from an EBV-seronegative donor [17].
Viral infection/reactivation other than EBV may also be a
critical issue, and donor lymphocyte infusion is not available
after CBT, although, in our series, the higher occurrence rate
of viral infection was proven only in BKV hemorrhagic
cystitis. However, 1 patient died of multiple viral diseases
(CMV and BKV) in the RIC-CBT group. Despite such a high
rate of viral infection after RIC-CBT, complete donor chime-
rism prevents relapse of primary disease (chronic EBVþ T/NK
cell LPD). Allogeneic immunity instead of antiviral immunity
may be the chief mechanism for controlling the primary
disease.
Finally, conditioning-associated HPSwas seen in 1 patient
with EBVþ T cell LPD and in 3 patients with EBVþNK cell LPD.
As shown in Figure 5, for example, UPN 603 experienced
typical conditioning-associated HPS and needed earlier and
longer administration of Etp (days e4, e3, and e1) than
scheduled (days e3 and e2). There was no relation between
EBV load just before RIC and occurrence of conditioning-
associated HPS (Table 3). Attention is required for HPS not
only after HSCT [18] but also after treatment with antithy-
mocyte globulin or an initiation of conditioning in patients
with chronic EBVþ T/NK cell LPD.
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HSCT in patients with chronic EBVþ T/NK cell LPD when
there is no HLA-matched sibling donor. No differences in EFS
and OS rates were found between patients treated with RIC-
BMT and those treated with RIC-CBT. The occurrence of
engraftment failure was slightly high in the RIC-CBT group,
but this was not signiﬁcant. The ratio of severe acute GVHD
might be smaller, and the rate of extensive chronic GVHD
was statistically lower after RIC-CBT. A higher incidence of
BKV hemorrhagic cystitis was documented after RIC-CBT.
There were no deaths from GVHD, but viral infection/reac-
tivation would be life threatening after RIC-CBT. Attention to
conditioning-associated HPS is necessary in patients with
chronic EBVþ T/NK cell LPD.
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